Literature DB >> 1268859

Tumorigenicity in vivo and induction of malignant transformation and mutagenesis in cell cultures by adriamycin and daunomycin.

H Marquardt, F S Philips, S S Sternberg.   

Abstract

The two anthracycline antitumor antibiotics, adriamycin and daunomycin, have been tested for tumorigenic activity, and the results confirm previous findings that they can induce mammary tumors in female rats receiving single i.v. doses. Both substances are highly potent in producing malignant transformation and mutation in mammalian cell systems in vitro. Their transformming activity is comparable to that of the potent carcinogen, N-methyl-N'-nitro-N-nitro-soguanidine. Actinomycin D, although similar to the anthracyclines in having high binding affinity for DNA, is only minimally effective in the same in vitro systems and its direct carcinogenic activity in vivo is moot. These results suggest that satisfactory correlations may be obtainable between tests for tumorigenicity in vivo, and assays for transformation and mutagenesis in vitro, and that adriamycin, and daunomycin may have carcinogenic potential in man.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1268859

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  [Initial results of the biocompatibility, cytotoxicity and genotoxicity of Aramid].

Authors:  J V Wening; U Langendorff; G Delling; H Marquardt; M Hoffmann; K H Jungbluth
Journal:  Unfallchirurgie       Date:  1989-10

Review 2.  Mutagenic effects of some anticancer antibiotics.

Authors:  B K Vig
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  The genotoxicity of lucidin, a natural component of Rubia tinctorum L., and lucidinethylether, a component of ethanolic Rubia extracts.

Authors:  J Westendorf; B Poginsky; H Marquardt; G Groth; H Marquardt
Journal:  Cell Biol Toxicol       Date:  1988-06       Impact factor: 6.691

Review 4.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

5.  Growth inhibition of human Tenon's capsule fibroblasts and rabbit dermal fibroblasts with non-carcinogenic N-alkylated anthracyclines.

Authors:  U H Steinhorst; E P Chen; S F Freedman; R Machemer; D L Hatchell
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-06       Impact factor: 3.117

6.  Detection of chemical carcinogens by assay of unscheduled DNA synthesis in rat tracheal epithelium in short-term organ culture.

Authors:  F Ide; T Ishikawa; S Takayama
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

7.  Phyllanthus maderaspatensis, a dietary supplement for the amelioration of adriamycin-induced toxicity and oxidative stress in mice.

Authors:  Praveen Bommu; Chandrasekar Moola Joghee Nanjan; Nanjan Moola Joghee; Satishkumar Muthureddy Nataraj; Suresh Bhojraj
Journal:  J Nat Med       Date:  2007-10-24       Impact factor: 2.343

8.  The mutagenic activity of anti-cancer drugs and the urine of rats given these drugs.

Authors:  K Pak; T Iwasaki; M Miyakawa; O Yoshida
Journal:  Urol Res       Date:  1979-06-22

9.  Induction of malignant transformation in vitro and mammary tumors in rats by two new potent anthracycline antitumor antibiotics, morpholinodaunomycin and cyanomorpholinoadriamycin.

Authors:  J Westendorf; U Mohr; H Marquardt
Journal:  Cell Biol Toxicol       Date:  1987-03       Impact factor: 6.691

10.  Breast Cancer Risk in Childhood Cancer Survivors Without a History of Chest Radiotherapy: A Report From the Childhood Cancer Survivor Study.

Authors:  Tara O Henderson; Chaya S Moskowitz; Joanne F Chou; Angela R Bradbury; Joseph Phillip Neglia; Chau T Dang; Kenan Onel; Danielle Novetsky Friedman; Smita Bhatia; Louise C Strong; Marilyn Stovall; Lisa B Kenney; Dana Barnea; Elena Lorenzi; Sue Hammond; Wendy M Leisenring; Leslie L Robison; Gregory T Armstrong; Lisa R Diller; Kevin C Oeffinger
Journal:  J Clin Oncol       Date:  2015-12-23       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.